Evaluation of a fast and fully automated platform to diagnoseEGFRandKRASmutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day.
OBJECTIVE
Searching forEGFRandKRASmutations within non-small cell lung carcinoma (NSCLC) samples remains time-consuming and can delay treatment choices in patients with acute deterioration. We evaluated the performances of the fully automated Idylla platform to quickly detect these mutations in NSCLC samples.


METHODS
We used the IdyllaEGFRMutation Assay and the IdyllaKRASMutation Test to analyse 18 formalin-fixed paraffin-embedded NSCLC tumour samples with knownEGFRandKRASmutation status according to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) forEGFRT790Mmutations.


RESULTS
Idylla assays identifiedKRASandEGFRactivating mutations in 4 and 10 NSCLC samples, respectively.EGFRT790Mresistance mutations were identified in only 1 sample using Idylla but in 4 and 14 samples using NGS and ddPCR, respectively. No false-positive result was noted with Idylla assays. Mutation written report was obtained after 130 min (KRASassays) to 140 min (EGFRassays).


CONCLUSIONS
The Idylla platform is an interesting ancillary first-line fast and fully automated tool to detectEGFRandKRASmutations in NSCLC samples allowing rapid treatment choices in patients with acute deterioration.
Department of Pathology, CHRU Brest, Brest, France.
Laetitia
L
Lambros
Department of Tumors Biology, CHU Bordeaux Haut-Lévêque, Pessac, France.
Charline
C
Caumont
Department of Pathology, CHRU Brest, Brest, France.
Briac
B
Guibourg
Department of Pathology, CHRU Brest, Brest, France.
Fanny
F
Barel
Department of Pathology, CHRU Brest, Brest, France.
Isabelle
I
Quintin-Roué
Department of Pathology, CHRU Brest, Brest, France.|Inserm, Brest, France.
Pascale
P
Marcorelles
Department of Tumors Biology, CHU Bordeaux Haut-Lévêque, Pessac, France.
Jean-Philippe
JP
Merlio
Department of Pathology, CHRU Brest, Brest, France.|Inserm, Brest, France.|European University of Brittany, France.
Arnaud
A
Uguen
D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000295:instrumentation; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*
C117307:KRAS protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)
EGFR; LUNG CANCER; MOLECULAR PATHOLOGY; PCR